Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-05-22
2007-05-22
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S254020, C514S254030, C544S121000, C544S367000, C544S369000
Reexamination Certificate
active
11324990
ABSTRACT:
The present invention relates to compounds of formula IwhereinR1,R2, X1, and X2are as defined in the specificationand to pharmaceutically acceptable acid addition salts thereof. Such compounds are inhibitors of the glycine transporter 1 (GlyT-1) and can be used in the treatment of schizophrenia, cognitive impairment, and Alzheimer's disease.
REFERENCES:
patent: 3933802 (1976-01-01), Ferrini et al.
patent: 4244871 (1981-01-01), Kosary et al.
patent: 2005/0059668 (2005-03-01), Alberati-Giani et al.
patent: 2005/0070539 (2005-03-01), Alberati-Giani et al.
patent: 2005/0209241 (2005-09-01), Jolidon et al.
patent: 0 171 636 (1985-02-01), None
patent: 0 624 584 (1994-11-01), None
patent: 867 273 (1961-05-01), None
patent: WO 99/44596 (1999-09-01), None
patent: WO 99/45011 (1999-09-01), None
patent: WO 02/22612 (2002-03-01), None
patent: WO 03/004480 (2003-01-01), None
patent: WO 03/035602 (2003-05-01), None
patent: WO 2004/037800 (2004-05-01), None
patent: WO 2005/014563 (2005-02-01), None
patent: WO 2005/023260 (2005-03-01), None
patent: WO 2005/023261 (2005-03-01), None
Petigra, R.B., et al., Journal of Medicinal Chemistry, 11(2), pp. 332-336 (1968), XP000590800.
Lewis D.A. & Lieberman J.A., Neuron. vol. 28, pp. 325-334 (2000).
Vandenberg R. J. & Aubrey K. R., Exp. Opin. Ther. Targets vol. 5(4) pp. 507-518 (2001).
Nakazato A. & Okuyama S., Exp. Opin. Ther. Patents vol. 10(1) pp. 75-98 (2000).
Sharma T., Br. J. Psychiatry, vol. 174 (Suppl. 38) pp. 44-51 (1999).
Javitt D. C. et al., Biol. Psychiatry, vol. 45 pp. 668-679 (1999).
Mohn A. R., Cell vol. 98 pp. 427-436 (1999).
Bliss, T. V. & Collingridge G. L., Nature, vol. 361 pp. 31-39 (1993).
Tang J. P. et al., Nature, vol. 401, pp. 63-69 (1999).
Gainetdinov R. R. et al., Trends in Pharm. Sci. vol. 23(8) pp. 367-373 (2002).
Lopez-Corcuera B, et al., Mol. Mem. Biol. vol. 18 pp. 13-20 (2001).
Bergeron R. et al., Proc. Natl. Acad. Sci. USA vol. 95, pp. 15730-15734 (1998).
Chen et al., J. Neurophysiol. vol. 89(2) pp. 691-703 (2003).
Armer R. E. & Miller D. J., Exp. Opin. Ther. Patents vol. 11(4) pp. 563-572 (2001).
Pralong E. et al., Prog. in Neurobiol. vol. 67, pp. 173-202 (2002).
Carlsson M. L., J. Neural Trans. vol. 105, pp. 525-535 (1998).
Kwong et al., Org. Lett. 4, pp. 581-584 (2002).
Kuwano et al., JOC 67, pp. 6479-6486 (2002).
Chem. Abstract XP-002299148 Chemcats No. 2004:3653471 (2004).
Caulfield W. L. et al., Journal of Med. Chem. vol. 44(17) pp. 2679-2682 (2001).
Chem. Abstract XP-002299149 Chemcats No. 2004:2179871 (2004).
Chemical Abstracts Service, Apr. 23, 2003, XP002308402, Database accession No. 2003: 2142911 Chemcats & Catalog: AsInExpress Gold.
Chemical Abstracts Service, Jun. 6, 2003, XP002308481 & Database Chemcats.
Chemical Abstracts Service, Jan. 1, 2004, XP002308405, Database accession No. 2003:2872406 Chemcats & Catalog: Ambinter Stock Screening Collection.
Chemical Abstracts Service, Jan. 1, 2004, XP002308403, Database accession No. 2004:591813 & Catalog: Ambinter Stock Screening Collection.
Chemical Abstracts Service, Jan. 1, 2004, XP002308404, Database accession No. 2004:660630 & Catalog: Ambinter Screening Library.
Chemical Abstracts Service, XP002308978 Chemcats No. 2002:330684 (2003).
Chemical Abstracts Service, XP002308979, CHEMCATS No. 2003:1026314 (2004).
Chemical Abstracts Service, XP002308980; CHEMCATS No. 2001;2814605 (2003).
Chemical Abstracts Service, XP002308981; CHEMCATS No. 2002:2063001 (2004).
Chemical Abstracts Service, XP002308983; CHEMCATS No. 2003:1026533 (2004).
Chemical Abstracts Service, XP002308984; CHEMCATS No. 2002:2288893 (2004).
Chemical Abstracts Service, XP002308985; CHEMCATS No. 2003:709504 (2004).
Chemical Abstracts Service, XP002308986; CHEMCATS No. 2003:709503 (2004).
Chemical Abstracts Service, XP002308987; CHEMCATS No. 2003:709505 (2004).
Chemical Abstracts Service, XP002308988; CHEMCATS No. 2004:1498769 (2004).
Chemical Abstracts Service, XP002308989; CHEMCATS No. 2002:2386068 (2004).
Chemical Abstracts Service, XP002308990; CHEMCATS No. 2002:2894607 (2004).
Chemical Abstracts Service, XP002308991; CHEMCATS No. 2003:3342164 (2004).
Chemical Abstracts Service, XP002308992; CHEMCATS No. 2003:3345505 (2004).
Chemical Abstracts Service, XP002308993; CHEMCATS No. 2003:3346187 (2004).
Chemical Abstracts Service, XP002309007; CHEMCATS No. 2004:660630.
Abstract corresponding to Document B5—WO 03/035602 (2003).
Cabiddu et al., Journal of Organometallic Chemistry, 1991, 419(1-2) 1-8.
Collins, et al., J. Med. Chem. 1998, 41, p. 5037-5054.
Jolidon Synese
Narquizian Robert
Norcross Roger David
Pinard Emmanuel
Bernhardt Emily
Hoffman-La Roche Inc.
Johnston George W.
Prior Kimberly J.
Rocha-Tramaloni Patricia S.
LandOfFree
Monocyclic substituted phenyl methanones does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monocyclic substituted phenyl methanones, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monocyclic substituted phenyl methanones will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3781074